What is NVS's current stock price?

As of now, NVS is trading at $132.36, with a daily change of +0.90%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

NVS Stock Analysis & IQ Rating | Novartis AG

NVS

Novartis AG

$132.36

+$1.18 | +0.90%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$134.24

MKT CAP

$280.99B

52W Low

$96.06

VOL

$1.58M

P/E Ratio

18.1

AVG VOL

$1.74M

RSI

57.51

TREND

Uptrend

NVS Stock IQ

Login to see Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NVS Target Price

Login to display

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Upgraded on attractively valued

NVS Rewards

Outperform the market

NVS Price Performance

$131.1 (+0.96%)

$122.29 (+8.23%)

$117.97 (+12.20%)

$98.4 (+34.51%)

1year

6month

3month

1month

NVS Risk Level

NVS has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

NVS Analysts Opinion

NVS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is positive and also has improved from the past 3 months

NVS Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

96%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NVS Street Sentiment

NVS Street Sentiment is extremely bullish and have positive views on the near-term outlook

NVS Performance Sentiment

Sentiments overview associated with NVS events and the stock performance.

96%

0%

Positive

Negative

27 out of 28
events present

0 out of 28
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$130.17

Resistance
Price

$123.43

Current Price Range

$133.72

Show methods +

Linked to NVS

IQ

Close Price

Change

PFE

3.94

25.80

+0.08%

AZN

4.31

90.29

-1.33%

SNY

4.02

48.86

+1.24%

REGN

4.20

746.80

+2.84%

MRK

4.03

99.01

+1.42%

NVS Latest Analysis +

Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan.

Wed Dec 10, 2025

$131.19 | +0.14%

Rating

Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia.

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Novartis Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder. NVS) on Tuesday shared results from the VAYHIT2 Phase3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously .In August Novartis topline results from the VAYHIT2 trial.Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% based on the primary endpoint of time to treatment failure (TTF) which assesses how long patients maintain safe

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Tiny Biotech Terns Takes Aim At Novartis Leukemia Blockbuster. ) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated patients at the American Society of Hematology Annual Meeting and Exposition.As of the cutoff date of September 13 2025 63 patients were enrolled.Of 38 efficacy-evaluable patients the overall (cumulative) major molecular response (MMR) rate was 74% (28/38) by 24 weeks with 64% (18/28) achieving MMR and 100% .Also Read: D

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Novartis inks $1.7 billion drug target agreement with UKs Relation Therapeutics.

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

JP Morgan Upgrades Novartis AG - Depositary Receipt (NVS). Fintel reports that on December 8 2025 JP Morgan upgraded their outlook for Novartis AG - Depositary Receipt (NYSE:NVS) from Neutral to Overweight. Analyst Price Forecast Suggests 2.18% Upside

Tue Dec 9, 2025

$131.01 | +0.63%

Rating

Novartis teams with UK biotech in $1.7 bln AI allergy drug deal – report.

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Avidity Biosciences Inc. (RNA): A Case Theory . We came across a ish thesis on Avidity Biosciences Inc. on BiotechBonanzas Substack by AnotherBio. In this article we will summarize the s thesis on RNA. Avidity Biosciences Inc.’.s share was trading at $71.54 as of December 2nd. Novartis is acquiring Avidity RNA a pre-Phase 3 biotech company in a straightforward deal with no overlap between the two businesses. The [….]

Thu Dec 4, 2025

$132.43 | -0.96%

Activity

Heres Why Novartis (NVS) is a Strong Value Stock. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Wed Dec 3, 2025

$133.72 | +1.09%

Potential

Novartis upgraded at Morgan Stanley on stock pullback Rhapsido launch.

Wed Dec 3, 2025

$133.72 | +1.09%

Activity

Rating

FAQ About NVS Stock Insights

What is NVS current stock price?

What are NVS stock strengths?

What is NVS Risk Level?

What is NVS market cap and volume?

What is NVS current Stock IQ?

Should I buy NVS stock right now?

Is NVS a Strong Buy right now?

What does a 'Strong Buy' rating mean for NVS?

What does a 'Strong Sell' rating mean for NVS?

What factors influence NVS's Stock IQ?

Explore our NVS Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored NVS Stock Strategies
Effective Risk Management

FIND US ON

Receive our NVS Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

NVS

Novartis AG

Current Price

$132.36

+$1.18 | +0.90%

52W High

$134.24

MKT CAP

$280.99B

52W Low

$96.06

VOL

$1.58M

P/E Ratio

18.1

AVG VOL

$1.74M

RSI

57.51

TREND

Uptrend

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

NVS Rewards

Earnings are forecast to grow

NVS Rewards

Upgraded on attractively valued

NVS Rewards

Outperform the market

Linked to NVS

Symbol

IQ

Close

Change

PFE

3.94

25.80

+0.08%

AZN

4.31

90.29

-1.33%

SNY

4.02

48.86

+1.24%

REGN

4.20

746.80

+2.84%

MRK

4.03

99.01

+1.42%

NVS Price Performance

$131.1 (+0.96%)

$122.29 (+8.23%)

$117.97 (+12.20%)

$98.4 (+34.51%)

1year

6month

3month

1month

NVS Analysts Opinion

NVS Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

NVS Analysts Opinion

NVS Analysts opinion is positive and also has improved from the past 3 months

NVS Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

96%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

NVS Street Sentiment

NVS Street Sentiment is extremely bullish and have positive views on the near-term outlook

NVS Risk Level

NVS has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

NVS Performance Sentiment

Sentiments overview associated with NVS events and the stock performance.

96%

0%

Positive

Negative

27 out of 28
events present

0 out of 28
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$130.17

Resistance
Price

$123.43

Current Price Range

$133.72

Show methods +

NVS Stock IQ

Login to unlock Novartis AG (NVS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

NVS Latest Analysis

Novartis AG (NVS) Gets Upgraded to Overweight from Neutral by JPMorgan.

Wed Dec 10, 2025

$131.19 | +0.14%

Rating

Novartis sees positive results when ianalumab added to Promacta for thrombocytopenia.

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Novartis Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder. NVS) on Tuesday shared results from the VAYHIT2 Phase3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously .In August Novartis topline results from the VAYHIT2 trial.Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% based on the primary endpoint of time to treatment failure (TTF) which assesses how long patients maintain safe

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Tiny Biotech Terns Takes Aim At Novartis Leukemia Blockbuster. ) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated patients at the American Society of Hematology Annual Meeting and Exposition.As of the cutoff date of September 13 2025 63 patients were enrolled.Of 38 efficacy-evaluable patients the overall (cumulative) major molecular response (MMR) rate was 74% (28/38) by 24 weeks with 64% (18/28) achieving MMR and 100% .Also Read: D

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Novartis inks $1.7 billion drug target agreement with UKs Relation Therapeutics.

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

JP Morgan Upgrades Novartis AG - Depositary Receipt (NVS). Fintel reports that on December 8 2025 JP Morgan upgraded their outlook for Novartis AG - Depositary Receipt (NYSE:NVS) from Neutral to Overweight. Analyst Price Forecast Suggests 2.18% Upside

Tue Dec 9, 2025

$131.01 | +0.63%

Rating

Novartis teams with UK biotech in $1.7 bln AI allergy drug deal – report.

Tue Dec 9, 2025

$131.01 | +0.63%

Activity

Avidity Biosciences Inc. (RNA): A Case Theory . We came across a ish thesis on Avidity Biosciences Inc. on BiotechBonanzas Substack by AnotherBio. In this article we will summarize the s thesis on RNA. Avidity Biosciences Inc.’.s share was trading at $71.54 as of December 2nd. Novartis is acquiring Avidity RNA a pre-Phase 3 biotech company in a straightforward deal with no overlap between the two businesses. The [….]

Thu Dec 4, 2025

$132.43 | -0.96%

Activity

Heres Why Novartis (NVS) is a Strong Value Stock. Whether youre a value growth or momentum investor finding strong stocks becomes easier with the Zacks Style Scores a top feature of the Zacks Premium research service.

Wed Dec 3, 2025

$133.72 | +1.09%

Potential

Novartis upgraded at Morgan Stanley on stock pullback Rhapsido launch.

Wed Dec 3, 2025

$133.72 | +1.09%

Activity

Rating

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVS. We're here to help you make informed investment decisions today.

FIND US ON

Receive our NVS Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVS Stock trends

NVS Stock performance

NVS Stock analysis

NVS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NVS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing NVS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

NVS Stock Analysis & IQ Rating | Novartis AG

NVS Stock IQ

NVS Target Price

NVS Risk Level

NVS Analysts Opinion

NVS Street Sentiment

NVS Performance Sentiment

Technical Price Levels

Explore our NVS Stock insights

Receive our NVS Daily Alerts

NVS Street Sentiment

NVS Risk Level

Technical Price Levels

Discover NVS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVS. We're here to help you make informed investment decisions today.

Receive our NVS Daily Alerts

NVS Runner Alarm